Jabra Enhance Select 200 vs Lexie B3

The Jabra Enhance Select 200 is a premium-priced OTC hearing aid that earned a B grade with a SoundScore of 3.9/5 in our lab testing, placing it in the top 35% of the OTC hearing aid category. At $1,695, this behind-the-ear device offers solid performance in several key areas, though it faces stiff competition from higher-scoring alternatives at similar price points. In our testing, this device showed particular strength in speech clarity during quiet listening situations, scoring 3.5/5—0.67 points above the category average. Own-voice comfort was another highlight at 3.4/5, finishing 0.89 points above average, which suggests users may find their own voice sounds more natural compared to many competitors. Music streaming scored 2.6/5, which is above the category average by 0.68 points but still only mixed in absolute terms. The device's limitations become apparent in challenging listening environments. Speech in noise scored just 1.4/5, slightly below the category average and low in absolute terms—a consideration for users who frequently encounter noisy restaurants or social gatherings. Feedback handling scored 4.0/5, which is strong in absolute terms though 0.54 points below the category average. The Enhance Select 200 has earned Expert's Choice Awards in both 2023 and 2024, reflecting its reliable real-world performance. With Bluetooth streaming for both iPhone and Android, rechargeable batteries, and hands-free capability, it offers modern convenience features. However, shoppers should note that several competitors in this price range—including the Lucid Tala and Audicus Omni 2—scored notably higher in our testing. This device is best suited for users who prioritize speech clarity in quieter environments and own-voice comfort over performance in noisy situations.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.